

## Ixempra ~ Ixabepilone

Distributed by: Bristol-Myers Squibb Company	FDA Approval: October 16, 2007
Class of Drug: Antineoplastic agent	Compendia Listing: Not available at this time
Dosing: 40 mg/m <sup>2</sup> IV over 3 hours every 3 weeks. Estimated number of median cycles for Ixempra and capecitabine regimen is 4. Estimated number of median cycles for Ixempra regimen alone is 5.	

### Indications

**Ixempra (combination therapy)** is indicated in combination with capecitabine for the treatment of metastatic or locally advanced breast cancer resistant to treatment with an anthracycline and a taxane or cancer that is taxane resistant and for which further anthracycline therapy is contraindicated. Anthracycline resistance is defined as progression while on therapy or within 6 months in the adjuvant setting or 3 months in the metastatic setting. Taxane resistance is defined as progression while on therapy or within 12 months in the adjuvant setting or 4 months in the metastatic setting.

**Ixempra (monotherapy)** is indicated as monotherapy for the treatment of metastatic or locally advanced breast cancer in patients whose tumors are resistant or refractory to anthracyclines, taxanes, and capecitabine.

**ICD-9:** 174 to 174.9

Codes/billing	Education material	Reimbursement program
<p>Ixempra billing code: J9999  Billing Units: Not available at this time  AWP: Not available at this time  ASP: Not available at this time</p> <p><b>Chemotherapy Drug</b></p> <ul style="list-style-type: none"> <li>● 15 mg Ixempra Kit SDV ~ NDC 0015-1910-12</li> <li>● 45 mg Ixempra Kit SDV ~ NDC 0015-1911-13</li> </ul> <p><b>Chemotherapy Infusion</b></p> <ul style="list-style-type: none"> <li>● 96413 First hour chemotherapy infusion</li> <li>● 96415 Additional hour chemo infusion – Qty 2</li> </ul> <p><b>Pre-Medication</b></p> <ul style="list-style-type: none"> <li>● H1 Antagonist (diphenhydramine 50 mg orally or equivalent) J1200</li> <li>● H2 Antagonist (ranitidine 150-300 mg orally or equivalent) J2780</li> <li>● Dexamethasone 20 mg IV, 30 minutes before infusion or orally, 60 minutes before infusion (<i>if necessary</i>) J1100</li> <li>● 90765 First hour non-chemotherapy infusion</li> </ul> <p><b><u>Supportive drugs</u></b></p> <ul style="list-style-type: none"> <li>○ GSF consideration (physician preference)</li> <li>○ ESA consideration (physician preference)</li> </ul> <p><b><u>Special cost consideration</u></b></p> <ul style="list-style-type: none"> <li>○ DEHP-free bag</li> <li>○ Lactated Ringer's solution 250 mL</li> <li>○ 0.2 to 1.2 micron tubing in-line filter</li> </ul>	<ul style="list-style-type: none"> <li>● BMSO nurse educator available by phone, printed nursing material available November 2007 <ul style="list-style-type: none"> <li>○ Consider scheduling nursing in-service with nurse educator from BMSO</li> </ul> </li> <li>● BMSO sales representative <ul style="list-style-type: none"> <li>○ Consider scheduling billing in-service with sales representative or billing educator from BMSO.</li> </ul> </li> <li>● Patient education material – provided on PI additional printed material available December 2007</li> </ul>	<ul style="list-style-type: none"> <li>● Destination access BMSO (800) 861-0048</li> </ul> <p>Provides</p> <ul style="list-style-type: none"> <li>● Letter of medical necessity</li> <li>● Insurance verification/authorization</li> <li>● Drug replacement for insured patient <ul style="list-style-type: none"> <li>○ Invoice cost</li> <li>○ Must be a US citizen or have proof of legal US status</li> <li>○ Total yearly household adjusted gross income &lt;\$75,000</li> <li>○ Diagnosis 174 – 174.9</li> </ul> </li> <li>● Drug replacement for indigent patient <ul style="list-style-type: none"> <li>○ Same criteria as above for free drug</li> </ul> </li> <li>● Co-pay assistance Referral to foundation</li> </ul> <p>Tips to discuss with your physician:</p> <ul style="list-style-type: none"> <li>● Will this drug replace a drug you currently stock? If so, consider adjusting your inventory min/max par levels for inventory control</li> <li>● Perform a data base search to find patients who can benefit from this new drug</li> </ul>